Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2021Frontiers in OncologyOpen Access

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGabriele RoccuzzoSGSilvia GiordanoPFPaolo Fava

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Roccuzzo et al. (2021) studied this question.

synapsesocial.com/papers/69f5aa02802deed698afb978https://doi.org/10.3389/fonc.2021.733770
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Foxp3 expression in cutaneous T‐cell lymphocytic infiltrates2008 · 37 citations
  2. 2Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up2018 · 279 citations
  3. 3Critical Role for Mast Cell Stat5 Activity in Skin Inflammation2014 · 90 citations
  4. 4Vascular endothelial growth factor A ( VEGFA ) expression in mycosis fungoides2014 · 18 citations
  5. 5Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas2004 · 108 citations